Incannex kicks off manufacture of skin therapeutics By: TheNewswire.com November 29, 2022 at 15:20 PM EST NASDAQ: IXHL) chief medical officer Dr Mark Bleakley tells Proactive they've engaged multinational contract development and manufacturing organisation (CDMO) Eurofins Scientific to manufacture the company’s topical ReneCann therapeutic cannabinoid formulation. ReneCann is a proprietary therapeutic developed to treat dermatological conditions caused by disorders of the immune system, including vitiligo, psoriasis and atopic dermatitis, otherwise known as eczema.">Contact DetailsProactive InvestorsJonathan Jackson+61 413 713 744Jonathan@proactiveinvestors.com
NASDAQ: IXHL) chief medical officer Dr Mark Bleakley tells Proactive they've engaged multinational contract development and manufacturing organisation (CDMO) Eurofins Scientific to manufacture the company’s topical ReneCann therapeutic cannabinoid formulation. ReneCann is a proprietary therapeutic developed to treat dermatological conditions caused by disorders of the immune system, including vitiligo, psoriasis and atopic dermatitis, otherwise known as eczema.">Contact DetailsProactive InvestorsJonathan Jackson+61 413 713 744Jonathan@proactiveinvestors.com